MAIA Biotechnology(MAIA)
Focus: MAIA Biotechnology is a publicly traded oncology-focused biotech company specializing in peptide cancer therapies with a pipeline targeting solid tumors. The company is headquartered in Chicago and operates as a clinical-stage developer with early-to-mid stage programs.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About MAIA Biotechnology
AI assessmentNot HiringNo open roles listed right now. Follow MAIA Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from MAIA Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$0K
Key Products
Post-LOE
Generic ANDA product with no marketed revenue or patent protection; minimal strategic value.
Help build intelligence for MAIA Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.